海尔生物收盘上涨1.02%，滚动市盈率29.70倍，总市值100.76亿元

Group 1 - The core viewpoint of the articles highlights Haier Biomedical's current market performance, including its stock price, PE ratio, and market capitalization, indicating a relatively low valuation compared to the industry average [1][3] - As of March 31, 2025, Haier Biomedical has 12,793 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company operates in two main sectors: life sciences and medical innovation, providing comprehensive digital solutions for various healthcare and research institutions [2] Group 2 - In the first quarter of 2025, Haier Biomedical reported a revenue of 689 million yuan, reflecting a year-on-year growth of 0.30%, while net profit decreased by 19.88% to 110 million yuan, with a gross margin of 48.35% [3] - The company's PE ratio stands at 29.70, significantly lower than the industry average of 52.34 and the median of 36.99, ranking it 62nd in the medical device sector [1][3] - Haier Biomedical's products and solutions are utilized in over 130 countries and regions, with collaborations established with more than 40 international organizations, including WHO and UNICEF [2]